This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Abiraterone will be available in a matter of weeks and will be offered to 7,000 men a year.

Benign prostatic hyperplasia (BPH) and overactive bladder (OAB) syndrome are distinct health conditions but may cause similar symptoms, such as urgent or frequent urination. BPH is the noncancerous ...